Clinical Trial

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Protocol Amendment History 4 changes
critical Trial completed 2026-08-01
critical Primary endpoint(s) modified 2026-08-01
notable Primary completion pushed: 2026-05 -> 2026-07-30 2026-08-01
minor Completion pushed: 2026-06 -> 2026-07-30 2026-08-01
Trial Details
NCT Number NCT06987513
Lead Sponsor Altimmune, Inc.
Conditions Alcohol Use Disorder (AUD)
Enrollment 100 participants
Start Date 2025-05-15
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31